Clinical Trials Browser

Phase 2 × NIH × ARQ 197 × Clear all

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

NCT01688973 2019-01-03

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

55 enrolled 16 charts

Genitourinary

Carcinoma, Renal Cell

NCT01696955 2018-12-19

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Phase 2 Completed

81 enrolled 14 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01519414 2018-09-12

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

78 enrolled 12 charts

Genitourinary

Prostatic Neoplasms

NCT01861301 2016-10-24

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Phase 2 Terminated

18 enrolled 7 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT01575522 2016-03-21

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2 Completed

22 enrolled 10 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer